MeiraGTx CMO reports RSU vesting, tax withholding

MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026.

Rhea-AI Filing Summary

MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, resulting in 35,000 restricted share units converting into the same number of ordinary shares at an exercise price of $0.

To cover taxes due on this vesting, 13,951 ordinary shares were automatically withheld and disposed of at a price of $7.42 per share. After these transactions, Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx. The filing indicates these are routine equity award vesting and tax-withholding events rather than open-market purchases or discretionary sales.

Insider Trade Summary

35,000 shares exercised/converted

Exercise 3 txns

Insider Zeldin Robert K

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	35,000	$0.00	$0.00
Exercise	Ordinary Shares	35,000	$0.00	$0.00
Exercise Price or Tax Liability	Ordinary Shares	13,951	$7.42	$104K

Holdings After Transaction: Restricted Share Units — 35,000 contracts (Direct); Ordinary Shares — 168,340 shares (Direct)

Footnotes (3)

1. F1. Represents vesting of one-half of restricted share units granted on January 17, 2024.
2. F2. Each restricted share unit converts into one ordinary share upon vesting.
3. F3. Shares withheld for payment of taxes upon vesting of award.

FAQ

What insider transaction did MeiraGTx (MGTX) report in this Form 4?

The Form 4 reports that Chief Medical Officer Robert K. Zeldin had 35,000 restricted share units vest, which converted into the same number of ordinary shares, with a portion of those shares withheld to pay taxes.

How many MeiraGTx (MGTX) RSUs vested for the CMO and on what date?

On January 17, 2026, 35,000 restricted share units vested for Chief Medical Officer Robert K. Zeldin, representing one-half of a prior RSU grant made on January 17, 2024.

Were the MeiraGTx (MGTX) RSU vesting transactions open-market purchases or sales?

No. The filing shows an M transaction code, meaning conversion of derivative securities (RSUs) into ordinary shares at $0 per share, and an F code for shares withheld to pay taxes, not discretionary open-market trades.

How many MeiraGTx (MGTX) shares were withheld for taxes and at what price?

The Form 4 states that 13,951 ordinary shares were withheld for payment of taxes upon vesting of the award at a price of $7.42 per share.

What is the MeiraGTx (MGTX) CMO’s share ownership after these transactions?

After the RSU vesting and related tax withholding, Chief Medical Officer Robert K. Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx Holdings plc.

What do the MeiraGTx (MGTX) Form 4 footnotes explain about the RSUs?

The footnotes explain that the transaction represents vesting of one-half of restricted share units granted on January 17, 2024, that each RSU converts into one ordinary share upon vesting, and that shares were withheld to pay taxes on the vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 09:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeldin Robert K

(Last) (First) (Middle)

655 THIRD AVENUE

SUITE 1115

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MeiraGTx Holdings plc [ MGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/17/2026		M		35,000(1)	A	(2)	182,291	D
Ordinary Shares	01/17/2026		F		13,951(3)	D	$7.42	168,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	01/17/2026		M			35,000	(1)	(1)	Ordinary Shares	35,000	$0	35,000	D

Explanation of Responses:

1. Represents vesting of one-half of restricted share units granted on January 17, 2024.

2. Each restricted share unit converts into one ordinary share upon vesting.

3. Shares withheld for payment of taxes upon vesting of award.

	/s/ Robert J. Wollin, Attorney-in-fact for Robert K. Zeldin	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.